Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro

Effective therapeutics are urgently needed to counter infection and improve outcomes for patients suffering from COVID-19 and to combat this pandemic. Manipulation of epigenetic machinery to influence viral infectivity of host cells is a relatively unexplored area. The bromodomain and extraterminal...

Descripción completa

Detalles Bibliográficos
Autores principales: Gilham, Dean, Smith, Audrey L., Fu, Li, Moore, Dalia Y., Muralidharan, Abenaya, Reid, St. Patrick M., Stotz, Stephanie C., Johansson, Jan O., Sweeney, Michael, Wong, Norman C. W., Kulikowski, Ewelina, El-Gamal, Dalia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072876/
https://www.ncbi.nlm.nih.gov/pubmed/33919584
http://dx.doi.org/10.3390/biomedicines9040437

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072876/
https://www.ncbi.nlm.nih.gov/pubmed/33919584
http://dx.doi.org/10.3390/biomedicines9040437

Ejemplares similares